{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T10:15:59Z","timestamp":1794564959234,"version":"4.9.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Clin Microbiol Antimicrob"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Antimicrobial resistance among nosocomial Gram-negative pathogens is a cause for concern in the Asia\u2013Pacific region. The aims of this study were to measure the rates of resistance among clinical isolates collected in Asia\u2013Pacific countries, and to determine the in vitro antimicrobial activities of ceftazidime\u2013avibactam and comparators against these isolates.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>CLSI broth microdilution methodology was used to determine antimicrobial activity and EUCAST breakpoints version 9.0 were used to determine rates of susceptibility and resistance. Isolates were also screened for the genes encoding extended-spectrum \u03b2-lactamases (ESBLs) or carbapenemases (including metallo-\u03b2-lactamases [MBLs]).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Between 2015 and 2017, this study collected a total of 7051 Enterobacterales isolates and 2032 <jats:italic>Pseudomonas aeruginosa<\/jats:italic> isolates from hospitalized patients in Australia, Japan, South Korea, Malaysia, the Philippines, Taiwan, and Thailand. In the Asia\u2013Pacific region, Enterobacterales isolates that were ESBL-positive, carbapenemase-negative (17.9%) were more frequently identified than isolates that were carbapenemase-positive, MBL-negative (0.7%) or carbapenemase-positive, MBL-positive (1.7%). Multidrug-resistant (MDR) isolates of <jats:italic>P. aeruginosa<\/jats:italic> were more commonly identified (23.4%) than isolates that were ESBL-positive, carbapenemase-negative (0.4%), or carbapenemase-positive, MBL-negative (0.3%), or carbapenemase-positive, MBL-positive (3.7%). More than 90% of all Enterobacterales isolates, including the ESBL-positive, carbapenemase-negative subset and the carbapenemase-positive, MBL-negative subset, were susceptible to amikacin and ceftazidime\u2013avibactam. Among the carbapenemase-positive, MBL-positive subset of Enterobacterales, susceptibility to the majority of agents was reduced, with the exception of colistin (93.4%). Tigecycline was active against all resistant subsets of the Enterobacterales (MIC<jats:sub>90<\/jats:sub>, 1\u20134\u00a0mg\/L) and among <jats:italic>Escherichia coli<\/jats:italic> isolates, &gt;\u200990% from each resistant subset were susceptible to tigecycline. More than 99% of all <jats:italic>P. aeruginosa<\/jats:italic> isolates, including MDR isolates and the carbapenemase-positive, MBL-positive subset, were susceptible to colistin.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>In this study, amikacin, ceftazidime\u2013avibactam, colistin and tigecycline appear to be potential treatment options for infections caused by Gram-negative pathogens in the Asia\u2013Pacific region.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12941-020-00355-1","type":"journal-article","created":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T11:02:47Z","timestamp":1585738967000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["In vitro activity of ceftazidime\u2013avibactam and comparators against Gram-negative bacterial isolates collected in the Asia\u2013Pacific region as part of the INFORM program (2015\u20132017)"],"prefix":"10.1186","volume":"19","author":[{"given":"Wen-Chien","family":"Ko","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory G.","family":"Stone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,4,1]]},"reference":[{"key":"355_CR1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx260","author":"RM Zellweger","year":"2017","unstructured":"Zellweger RM, Carrique-Mas J, Limmathurotsakul D, Day NPJ, Thwaites GE, Baker S, Southeast Asia Antimicrobial Resistance Network. A current perspective on antimicrobial resistance in Southeast Asia. J Antimicrob Chemother. 2017. https:\/\/doi.org\/10.1093\/jac\/dkx260.","journal-title":"J Antimicrob Chemother"},{"key":"355_CR2","doi-asserted-by":"publisher","DOI":"10.1186\/s13756-016-0115-6","author":"N Suwantarat","year":"2016","unstructured":"Suwantarat N, Carroll KC. Epidemiology and molecular characterization of multidrug-resistant Gram-negative bacteria in Southeast Asia. Antimicrob Resist Infect Control. 2016. https:\/\/doi.org\/10.1186\/s13756-016-0115-6.","journal-title":"Antimicrob Resist Infect Control"},{"key":"355_CR3","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02379-15","author":"KM Kazmierczak","year":"2015","unstructured":"Kazmierczak KM, Rabine S, Hackel M, McLaughlin RE, Biedenbach DJ, Bouchillon SK, et al. Multiyear, multinational survey of the incidence and global distribution of metallo-\u03b2-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2015. https:\/\/doi.org\/10.1128\/AAC.02379-15.","journal-title":"Antimicrob Agents Chemother"},{"key":"355_CR4","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00042-16","author":"LY Hsu","year":"2017","unstructured":"Hsu LY, Apisarnthanarak A, Khan E, Suwantarat N, Ghafur A, Tambyah PA. Carbapenem-resistant Acinetobacter baumannii and Enterobacteriaceae in South and Southeast Asia. Clin Microbiol Rev. 2017. https:\/\/doi.org\/10.1128\/CMR.00042-16.","journal-title":"Clin Microbiol Rev"},{"key":"355_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2019.07.019","author":"MD Malchione","year":"2019","unstructured":"Malchione MD, Torres LM, Hartley DM, Koch M, Goodman J. Carbapenem and colistin resistance in Enterobacteriaceae in Southeast Asia: review and mapping of emerging and overlapping challenges. Int J Antimicrob Agents. 2019. https:\/\/doi.org\/10.1016\/j.ijantimicag.2019.07.019.","journal-title":"Int J Antimicrob Agents"},{"key":"355_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgar.2017.05.025","author":"MA Pfaller","year":"2017","unstructured":"Pfaller MA, Shortridge D, Sader HS, Flamm RK, Castanheira M. Ceftolozane\u2013tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in Australia and New Zealand: report from an Antimicrobial Surveillance Program (2013\u20132015). J Glob Antimicrob Resist. 2017. https:\/\/doi.org\/10.1016\/j.jgar.2017.05.025.","journal-title":"J Glob Antimicrob Resist"},{"key":"355_CR7","doi-asserted-by":"publisher","DOI":"10.5694\/mja2.50249","author":"DA Williamson","year":"2019","unstructured":"Williamson DA, Howden BP, Paterson DL. The risk of resistance: what are the major antimicrobial resistance threats facing Australia? Med J Aust. 2019. https:\/\/doi.org\/10.5694\/mja2.50249.","journal-title":"Med J Aust"},{"key":"355_CR8","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkw239","author":"M Falcone","year":"2016","unstructured":"Falcone M, Paterson D. Spotlight on ceftazidime\/avibactam: a new option for MDR Gram-negative infections. J Antimicrob Chemother. 2016. https:\/\/doi.org\/10.1093\/jac\/dkw239.","journal-title":"J Antimicrob Chemother"},{"key":"355_CR9","unstructured":"Allergan. Avycaz (ceftazidime\u2013avibactam) for injection, for intravenous use: prescribing information. Madison: Allergan. 2017. https:\/\/www.allergan.com\/assets\/pdf\/avycaz_pi. Accessed 29 Aug 2019."},{"key":"355_CR10","unstructured":"Pfizer. Zavicefta: summary of product characteristics. Groton: Pfizer. 2016. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/zavicefta-epar-product-information_en.pdf. Accessed 29 Aug 2019."},{"key":"355_CR11","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02569-17","author":"JA Karlowsky","year":"2018","unstructured":"Karlowsky JA, Kazmierczak KM, Bouchillon SK, de Jonge BLM, Stone GG, Sahm DF. In vitro activity of ceftazidime\u2013avibactam against clinical isolates of Enterobacteriaceae and Pseudomonas aeruginosa collected in Asia-Pacific countries: results from the INFORM global surveillance program, 2012 to 2015. Antimicrob Agents Chemother. 2018. https:\/\/doi.org\/10.1128\/AAC.02569-17.","journal-title":"Antimicrob Agents Chemother"},{"key":"355_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgar.2019.07.003","author":"E Ramalheira","year":"2019","unstructured":"Ramalheira E, Stone GG. Longitudinal analysis of the in vitro activity of ceftazidime\/avibactam versus Enterobacteriaceae, 2012\u20132016. J Glob Antimicrob Resist. 2019. https:\/\/doi.org\/10.1016\/j.jgar.2019.07.003.","journal-title":"J Glob Antimicrob Resist"},{"key":"355_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2019.05.007","author":"GG Stone","year":"2020","unstructured":"Stone GG, Smayevsky J, Kazmierczak K. Longitudinal analysis of the in vitro activity of ceftazidime\u2013avibactam vs. Pseudomonas aeruginosa, 2012\u20132016. Diagn Microbiol Infect Dis. 2020. https:\/\/doi.org\/10.1016\/j.diagmicrobio.2019.05.007.","journal-title":"Diagn Microbiol Infect Dis"},{"key":"355_CR14","volume-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. CLSI standard M07","author":"Clinical and Laboratory Standards Institute (CLSI)","year":"2015","unstructured":"Clinical and Laboratory Standards Institute (CLSI). Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. CLSI standard M07. 10th ed. Wayne: CLSI; 2015.","edition":"10"},{"key":"355_CR15","unstructured":"The European Committee on Antimicrobial Susceptibility Testing (EUCAST). Breakpoint tables for interpretation of MICs and zone diameters. Version 9.0, 2019. http:\/\/www.eucast.org. Accessed 21 Aug 2019."},{"key":"355_CR16","doi-asserted-by":"publisher","DOI":"10.1128\/aac.05186-14","author":"SH Lob","year":"2015","unstructured":"Lob SH, Kazmierczak KM, Badal RE, Hackel MA, Bouchillon SK, Biedenbach DJ, et al. Trends in susceptibility of Escherichia coli from intra-abdominal infections to ertapenem and comparators in the United States according to data from the SMART program, 2009 to 2013. Antimicrob Agents Chemother. 2015. https:\/\/doi.org\/10.1128\/aac.05186-14.","journal-title":"Antimicrob Agents Chemother"},{"key":"355_CR17","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00220-16","author":"WW Nichols","year":"2016","unstructured":"Nichols WW, de Jonge BL, Kazmierczak KM, Karlowsky JA, Sahm DF. In vitro susceptibility of global surveillance isolates of Pseudomonas aeruginosa to ceftazidime\u2013avibactam (INFORM 2012 to 2014). Antimicrob Agents Chemother. 2016. https:\/\/doi.org\/10.1128\/AAC.00220-16.","journal-title":"Antimicrob Agents Chemother"},{"key":"355_CR18","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2011.03570.x","author":"AP Magiorakos","year":"2012","unstructured":"Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012. https:\/\/doi.org\/10.1111\/j.1469-0691.2011.03570.x.","journal-title":"Clin Microbiol Infect"},{"key":"355_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2014.00643","author":"AO Olaitan","year":"2014","unstructured":"Olaitan AO, Morand S, Rolain JM. Mechanisms of polymyxin resistance: acquired and intrinsic resistance in bacteria. Front Microbiol. 2014. https:\/\/doi.org\/10.3389\/fmicb.2014.00643.","journal-title":"Front Microbiol"},{"key":"355_CR20","doi-asserted-by":"publisher","DOI":"10.3904\/kjim.2018.028","author":"YA Kim","year":"2018","unstructured":"Kim YA, Park YS. Epidemiology and treatment of antimicrobial-resistant Gram-negative bacteria in Korea. Korean J Intern Med. 2018. https:\/\/doi.org\/10.3904\/kjim.2018.028.","journal-title":"Korean J Intern Med"},{"key":"355_CR21","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.ES.2018.23.42.1800047","author":"H Lee","year":"2016","unstructured":"Lee H, Yoon EJ, Kim D, Jeong SH, Won EJ, Shin JH, et al. Antimicrobial resistance of major clinical pathogens in South Korea, May 2016 to April 2017: first one-year report from Kor-GLASS. Euro Surveillance. 2016. https:\/\/doi.org\/10.2807\/1560-7917.ES.2018.23.42.1800047.","journal-title":"Euro Surveillance"},{"key":"355_CR22","doi-asserted-by":"publisher","DOI":"10.2147\/IDR.S193638","author":"CH Liao","year":"2019","unstructured":"Liao CH, Lee NY, Tang HJ, Lee SS, Lin CF, Lu PL, et al. Antimicrobial activities of ceftazidime\u2013avibactam, ceftolozane\u2013tazobactam, and other agents against Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa isolated from intensive care units in Taiwan: results from the Surveillance of Multicenter Antimicrobial Resistance in Taiwan in 2016. Infect Drug Resist. 2019. https:\/\/doi.org\/10.2147\/IDR.S193638.","journal-title":"Infect Drug Resist"},{"key":"355_CR23","doi-asserted-by":"publisher","DOI":"10.2147\/IDR.S208231","author":"YT Chang","year":"2019","unstructured":"Chang YT, Siu LK, Wang JT, Wu TL, Chen YH, Chuang YC, et al. Resistance mechanisms and molecular epidemiology of carbapenem-nonsusceptible Escherichia coli in Taiwan, 2012\u20132015. Infect Drug Resist. 2019. https:\/\/doi.org\/10.2147\/IDR.S208231.","journal-title":"Infect Drug Resist"},{"key":"355_CR24","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cix783","author":"D van Duin","year":"2018","unstructured":"van Duin D, Lok JJ, Earley M, Cober E, Richter SS, Perez F, et al. Colistin versus ceftazidime\u2013avibactam in the treatment of infections due to carbapenem-resistant Enterobacteriaceae. Clin Infect Dis. 2018. https:\/\/doi.org\/10.1093\/cid\/cix783.","journal-title":"Clin Infect Dis"},{"key":"355_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2019.00080","author":"CC Sheu","year":"2019","unstructured":"Sheu CC, Chang YT, Lin SY, Chen YH, Hsueh PR. Infections caused by carbapenem-resistant Enterobacteriaceae: an update on therapeutic options. Front Microbiol. 2019. https:\/\/doi.org\/10.3389\/fmicb.2019.00080.","journal-title":"Front Microbiol"},{"key":"355_CR26","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofy343","author":"D Shortridge","year":"2019","unstructured":"Shortridge D, Gales AC, Streit JM, Huband MD, Tsakris A, Jones RN. Geographic and temporal patterns of antimicrobial resistance in Pseudomonas aeruginosa over 20\u00a0years from the SENTRY antimicrobial surveillance program, 1997\u20132016. Open Forum Infect Dis. 2019. https:\/\/doi.org\/10.1093\/ofid\/ofy343.","journal-title":"Open Forum Infect Dis"},{"key":"355_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(15)00424-7","author":"YY Liu","year":"2016","unstructured":"Liu YY, Wang Y, Walsh TR, Yi LX, Zhang R, Spencer J, et al. Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study. Lancet Infect Dis. 2016. https:\/\/doi.org\/10.1016\/S1473-3099(15)00424-7.","journal-title":"Lancet Infect Dis"},{"key":"355_CR28","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00774-09","author":"D Yong","year":"2009","unstructured":"Yong D, Toleman MA, Giske CG, Cho HS, Sundman K, Lee K, et al. Characterization of a new metallo-\u03b2-lactamase gene, blaNDM-1, and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India. Antimicrob Agents Chemother. 2009. https:\/\/doi.org\/10.1128\/AAC.00774-09.","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Annals of Clinical Microbiology and Antimicrobials"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12941-020-00355-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12941-020-00355-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12941-020-00355-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,31]],"date-time":"2021-03-31T23:10:44Z","timestamp":1617232244000},"score":1,"resource":{"primary":{"URL":"https:\/\/ann-clinmicrob.biomedcentral.com\/articles\/10.1186\/s12941-020-00355-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,1]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["355"],"URL":"https:\/\/doi.org\/10.1186\/s12941-020-00355-1","relation":{},"ISSN":["1476-0711"],"issn-type":[{"value":"1476-0711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,1]]},"assertion":[{"value":"21 January 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"WCK has no competing interests to declare. GGS is an employee and a shareholder of Pfizer Inc., and is also a shareholder of AstraZeneca.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"14"}}